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 EFFECT OF SIMVASTATIN ON THE 
GROWTH INHIBITION OF Candida 
albicans 
_______________________________________________________ 
 
ABSTRACT 
 
Yeasts of the Candida genus often interact in a commensal colo-
niser of humans. However, in certain conditions they can cause 
infections such as superficial or systemic candidiasis, which are 
responsible for high mortality rates because of ineffective diagno-
ses and treatments. The mechanisms associated with the virulence 
of Candida albicans must be understood since they have acquired 
growing importance due to their increased resistance to drugs 
such as Fluconazole and Amphotericin B, both commonly used in 
therapeutic hospital routines. The present study evaluated the sen-
sibility of isolated C. albicans to simvastatin, which acts on the 
ergosterol of the plasma membrane of this fungus. The sensitivity 
profile of the isolated C. albicans ATCC 90028 to simvastatin 
was determined by the agar diffusion methodology. The concen-
tration of simvastatin used ranged from 78 to 2500µg.mL
-1
. The 
results obtained demonstrated that simvastatin has great potential 
for being used against C. albicans. 
 
Keywords: Simvastatin. Antifungal Action. Candida albicans. 
Sensibility. Fluconazole. 
 
 
EFEITO DA AÇÃO DA SINVASTATINA 
NA INIBIÇÃO DO CRESCIMENTO DE 
Candida albicans 
_______________________________________________________ 
 
RESUMO 
 
Leveduras do gênero Candida muitas vezes interagem como 
colonizadoras comensais de humanos. No entanto, em certas 
condições, podem causar infecções, como a candidíase superficial 
ou sistêmica, que são responsáveis por altas taxas de mortalidade 
devido à diagnósticos e tratamentos ineficazes. Os mecanismos 
associados à virulência de Candida albicans devem ser 
entendidos, uma vez que adquiriram importância crescente devido 
à sua maior resistência a medicamentos como Fluconazole e 
Anfotericina B, ambos comumente usados em rotinas hospitalares 
terapêuticas. O presente estudo avaliou a sensibilidade de isolado 
de C. albicans à sinvastatina, que atua no ergosterol da membrana 
plasmática desse fungo. O perfil de sensibilidade do C. albicans 
isolado ATCC 90028 a sinvastatina foi determinado pela 
metodologia de difusão em ágar. A concentração de sinvastatina 
utilizada variou de 78 a 2500 μg.mL-1. Os resultados obtidos 
demonstraram que sinvastatina tem um grande potencial para ser 
usado contra C. albicans. 
 
Palavras-chave: Sinvastatina. Atividade antifúngica. Candida 
albicans. Sensibilidade. Fluconazol. 
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1 INTRODUCTION  
 
The Candida genus is formed by almost 
200 species, and approximately 10 are responsible 
for infections in man and cause superficial or 
invasive mycoses. The most important species is 
C. albicans accounting for about 50 to 70% of all 
invasive infections by the Candida genus 
(TORRES; LIMA; UEDA, 2016).  
Until the mid-twentieth century, reports of 
invasive yeast infections of Candida genus were 
scarce, but for the past 20 years, the incidence of 
systemic infections has greatly increased (DE 
MELLO et al, 2017). The increase in the 
frequency of infections by Candida species in the 
last decades has made candidiasis an infection 
present in hospitals (SUTTON et al, 2017) 
Triazolic agents, such as fluconazole and 
itraconazole, which are administered orally or 
intravenously in hospital use, are the drugs most 
used in the treatment of mycoses and are useful in 
the prophylaxis of patients at risk of developing 
fungal infections, as they are less toxic than 
polyenes (DEL POETA, 2016; AHMAD, 2016). 
These drugs have good oral acceptance, a low 
incidence of side effects after being introduced, a 
new era in the treatment of fungal infections has 
started (CAMPOY, ADRIO, 2017). 
Azole agents interfere in the biosynthesis 
of ergosterol, the sterol present in the plasma 
membrane of fungi. Their mechanism of action 
occurs by inhibiting the enzyme 14α-demethylase 
(14 DM), an important cytochrome P-450 enzyme 
in the ergosterol biosynthesis route, which cata-
lyzes the oxidative removal of the 14α-methyl 
group from lanosterol (ZHANG et al, 2016; 
NIWA; IMAGAWA, 2016; SUI et al, 2017). Az-
ole, bound to the active site of this enzyme, com-
petes with the substrate for binding). An interrup-
tion in ergosterol production in fungi is lethal, as 
it affects cytokinesis, preventing cell growth and 
increasing the chances of the membrane collaps-
ing (WARRILOW et al, 2016; CHENGE et al, 
2017). 
Ergosterol, as well as cholesterol, 
stabilize and modulate membrane fluidity and 
permeability, as well as modulate enzymatic 
activities linked to the membrane and ion 
channels (ALCAZAR-FUOLI; MELLADO, 2013; 
LONG et al, 2016). The biochemical route to 
ergosterol formation is similar to that of 
cholesterol. 
After a long time, it was observed that the 
treatment with the azoles was failing. Some 
studies have reported that one of the reasons for 
this failure was due to the resistance of Candida 
to antifungal agents (MONROY-PÉREZ et al, 
2016; MEIS et al, 2016; LEONARDELLI et al, 
2017). This fact warns for need to develop 
strategies to prevent the spread of the species 
among fungi, as has already occurred with 
bacteria, which are now widespread and out of 
control (Thangamani et al, 2015; ZHANG et al, 
2017). 
Studies conducted by Rahal et al (2015)
 
have indicated clinical benefits for the use of 
statins during the treatment of infections and 
sepsis. Atorvastatin was used intraperitoneally in 
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mice infected with C. albicans and the effect of 
this statin was to increase the survival of the mice 
by inhibition of C. albicans. In 2006 Macreadie, 
et al had already studied the effects of the two 
major statins, simvastatin and atorvastatin, on five 
species of Candida and Aspergillus fumigatus. 
Statins strongly inhibited the growth of all species 
except Candida krusei. The antimicrobial effects 
of statins against various oral and skin 
microorganisms (THANGAMANI et al, 2015) 
have also been studied. Simvastatin is most 
effective against the periodontal pathogens 
Aggregatibacter actinomycetemcomitans and 
Porphyromonas gingivalis, and against most 
dental plaque bacteria, including Streptococcus 
mutans. Statins also exhibited antiviral properties 
against human cytomegalovirus, hepatitis B virus 
and hepatitis C virus, and have antifungal 
properties against Candida albicans, Aspergillus 
fumigatus and Zygomycetes spp (TING; 
WHITAKER; ALBANDAR, 2016).  
New therapeutic strategies are needed to 
prevent the spread of resistance. Among these 
strategies, we can highlight the search for new 
drugs and combinations of drugs with synergic 
purpose, that is, to perform combinations where 
the result of this union is better than the action of 
each drug acting separately (MENEZES et al, 
2012). 
Statins are drugs used to treat 
hypercholesterolemia, but may also have some 
antifungal activity. They act by inhibiting the 
enzyme 3-hydroxy-3-methylglutaryl reductase 
(HMG-CoA) and reduce the level of cholesterol 
synthesis intermediates. In vitro studies have 
shown that simvastatin inhibits the growth of 
Candida spp. In addition, may be useful in the 
treatment of candidiasis (MENEZES et al, 2012). 
Yeasts use the same enzyme pathway, but 
the end product is ergosterol. 
As reported in the studies, statins strongly 
inhibited the growth of some Candida species and 
the results then suggested that statins may have 
utility as antifungal agents and that fungal 
colonization could be affected by statin therapy 
(MACREADIE et al., 2006; MENEZES et al, 
2012; THANGAMANI et al, 2015; TING; 
WHITAKER; ALBANDAR, 2016; HENNESSY 
et al, 2016). 
Disk diffusion susceptibility testing is 
widely used for antibacterial compounds in 
routine clinical microbiology laboratories, and 
thus, this concept is attractive for antifungal 
susceptibility testing. The CLSI (2015) has 
approved a disk diffusion methodology for the 
testing of several antifungals (document M44-
A2). 
This study aimed to evaluate the in vitro 
antimicrobial potential of simvastatin in C. 
albicans and to determine the minimum inhibitory 
concentration (MIC). 
 
 
2 MATERIAL AND METHODS 
 
For the study was used standard strain of 
Candida albicans ATCC 90028, belonging to the 
Department of Microbiology and Immunology of 
the Federal University of Alfenas, Brazil. The 
purity and identity of the C. albicans strain was 
confirmed by growth on chromogenic medium 
and microscopical and biochemical features. 
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Disk diffusion and assays were performed 
strictly according to CLSI (2015) documents 
M44-A2 of the Clinical and Laboratory Standards 
Institute. The tests were performed in triplicate 
and visually read after 24 h of incubation at 35
o
C. 
The inoculums were prepared obtaining a final 
concentration of 0.5 × 10
8
 cells mL
−1
. Two sam-
ples of simvastatin were used, one standard 
(Pharma Nostra Pharmaceutical Ingredients, Rio 
de Janeiro, RJ, Brazil) named standard (P), and 
the other commercial sample (A) (Sandoz, São 
Paulo-SP, Brazil) were used in the study. 
Wells of 12 mm diameter were made into 
petri dishes containing Mueller Hinton agar pre-
pared in advance. With a sterile swab, the C. albi-
cans inoculum was evenly distributed over the 
surface of the agar, allowed to stand at room tem-
perature for approximately 3 minutes. Fifty mi-
croliters of the positive and negative controls, as 
well as of each concentration of standard and 
sample simvastatin (78, 156, 312, 625, 1250 
μg.mL-1) were dispensed into each properly iden-
tified well using an automatic pipette. The plates 
were incubated for 24 hours at 35 ± 1
o
 C (RIOS; 
RECIO; VILLAR, 1988; VANDEN BERGHE; 
VLIETINCK, 1991; SILVEIRA et al, 2009). The 
tests were performed in triplicate. 
The growth inhibition halo was measure 
in millimeters using a digital caliber. As negative 
control was used sterile water and fluconazole at 
256 μg mL-1 as positive control. A test with 
DMSO diluted 1:1 in distilled water was also 
done to evaluate the action of the same on C. al-
bicans. 
The results of the biological assays were 
obtained using Student's t test for each concentra-
tion, with post-test of Mann-Whitney, in the com-
parison between standard and sample, at the sig-
nificance level of 5% (RUXTON, 2006). 
 
 
3 RESULTS AND DISCUSSION 
 
It was observed that in DMSO, there was 
a complete dilution of simvastatin, but since 
DMSO is a potent inhibitor, only the stock solu-
tion (2500 μg / mL) was performed with this sol-
vent, the other dilutions were made in purified 
water. In this test of the action of DMSO on 
simvastatin, it was observed that the dilution used 
did not interfere in the growth of the yeast. 
In the well-agar agar diffusion assays, it 
was found that simvastatin inhibited the growth 
C. albicans, with formation of inhibition halos 
around the wells where the solutions tested were 
deposited. 
In the comparison between sample and 
standard, both had similar behavior in inhibiting 
the growth of C. albicans. Table I presents the 
results of growth inhibition halos measurements 
of C. albicans for standard and sample 
simvastatin. 
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Table I - Mean of halos measurement (mm) for sensitivity test by disc-diffusion method in agar 
  
Mean ± SD of halos measurement (mm) 
Candida albicans 90028 
Concentration of Simvastatin µg.mL-1 
Mean SD Mean SD 
P P A A 
78 9.6 0.058 9.9 0.058 
156 13.3 0.1 14.5 0.058 
312 16.1 0.058 16.8 0.115 
625 18.5 0.1 17.9 0.153 
1250 22.9 0.058 22 0.252 
Fluconazole (C+) 25 
 
24.5 
 Purified water (C-)        -          -   
     A: sample;  C+: positive control;  C-: negative control;  P: standard; SD: standard deviation 
 
 
As can be seen in Figure 1, there were no 
significant differences when comparing the 
standard with the sample on inhibition of the C. 
albicans ATCC strain, suggesting that both the 
pharmaceutical standard and the commercial 
sample have antimicrobial effect. 
The objective of the microbiological 
assay was to evaluate the inhibition of growth of 
the microorganism by the simvastatin test and to 
evaluate the lowest concentration capable of 
achieving this inhibition. An advantage of this 
type of determination is that it does not require 
specialized and costly equipment and does not use 
solvents that are potentially toxic to the analyst 
and the environment (CARTER et al, 2017; 
DEGTYAREVA et al, 2017; COORENS et al, 
2017). 
 
 
 
Figure 1: Comparison of growth inhibitory halos measurements for C. albicans ATCC 90028. P: standard and A: sample 
 
P: standard; A: sample 
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Technological progress, together with sci-
entific knowledge, has made possible a greater 
sensitivity of diagnostic methods and, in a similar 
way, has facilitated the identification of a diversi-
ty of yeast species in the laboratory of clinical 
analyzes or clinical mycology that have decreased 
sensitivity and resistance to fluconazole, and re-
ports of the occurrence of Candida spp. Re-
sistance in vitro to the different antifungal agents, 
has increased the researchers interest in antifungal 
sensitivity monitoring of clinical isolates to pre-
dict clinical response to therapy, although re-
sistance is still an uncommon phenomenon 
(THANGAMANI et al, 2015; ZHANG et al, 
2016; MONROY-PÉREZ et al, 2016; MEIS et al, 
2016; LEONARDELLI
 
 et al, 2017). 
Statins are inhibitors of the enzyme 3 - 
hydroxy - 3 - methyl - glutaryl - coenzyme A 
(HMG - CoA) reductase, leading to cholesterol 
production management (SLUYTER et al, 2016; 
SMITH et al. 2017; WADIA et al, 2017). Among 
the various statins, there is simvastatin, an HMG-
CoA reductase inhibitor, which has been widely 
used in clinical practice, in controlling cholesterol 
levels. 
Thus, in addition to its lipid-lowering 
function, this statin is notable for other side ef-
fects, including anti-inflammatory (PETRIS; 
SOUZA; BORTOLETTO, 2016), immunomodu-
latory, antioxidant, as well as the promotion of 
angiogenesis and increased differentiation of os-
teoblasts, inducing bone formation (SANTOS; 
BARACHO, 2015). Such properties offer great 
potential for statins also to possess antimicrobial 
potential. 
Several authors (CHAMILOS; LEWIS; 
KONTOYIANNIS, 2006; CABRAL; 
FIGUEROA; FARIÑA, 2013) presented the 
association of simvastatin with other antibiotics, 
which considerably reduced the growth of 
endodontic microorganisms. They also 
investigated the antifungal action of statins on 
zygomycetes and observed considerable 
fungicidal activity in vitro against all seven 
Zygomycetes isolates tested. The inhibitory 
activity of simvastatin on the growth of Candida 
and Cryptococcus yeasts with an inhibitory effect 
against both planktonic cells and biofilms was 
demonstrated by Brilhante et al (2015). The MICs 
of simvastatin against C. albicans and C. 
tropicalis were similar to serum levels of the drug 
when administered to control blood cholesterol.  
In the current research, the antimicrobial 
activity of simvastatin against Candida albicans 
ATCC 90028 was analyzed. It has been observed 
that simvastatin has an antifungal action against 
C. albicans and emphasizes its antifungal 
potential as described in other works (CABRAL; 
FIGUEROA; FARIÑA, 2013; BRILHANTE et al, 
2015). The MIC results identified 78µg / mL as 
the lowest concentration capable of inhibiting the 
growth of Candida albicans. 
This action is possibly due to the 
inhibition of the enzyme 14α-demethylase (14 
DM), an important cytochrome P-450 enzyme in 
the ergosterol biosynthesis route, which catalyzes 
the oxidative removal of the 14α-methyl group 
from lanosterol (ZHANG et al, 2016; NIWA; 
IMAGAWA, 2016; SUI et al, 2017). The 
blockade of simvastatin-induced ergosterol 
synthesis has been corroborated by bioassays by 
several authors, causing this statin to become a 
potential antifungal agent. 
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4 CONCLUSION 
 
The recommendations of the medicine 
help considerably in the search and selection of 
new pharmacological models to be used as an 
alternative to the conventional treatments. Given 
that the Candida genus is already resistant to 
azoles, the use of simvastatin as a potent growth 
inhibitor of these microorganisms appears as an 
alternative. The tests developed to evaluate the in 
vitro antimicrobial activity of simvastatin 
evidenced a capacity of inhibition of the growth 
of Candida albicans. With this evaluation and 
determination of the MIC, new perspectives are 
opened for the performance of pharmacokinetic 
studies in order to determine doses for in vivo 
research. 
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